Larson Financial Group’s Nuvation Bio NUVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$330 Buy
59
+31
+111% +$194 ﹤0.01% 3652
2026
Q2
$159 Buy
+28
New +$137 ﹤0.01% 3619
2025
Q4
– Sell
-5,400
Closed -$20K – 3605
2025
Q3
$20K Hold
5,400
– – ﹤0.01% 1649
2025
Q2
$10.5K Buy
5,400
+1,400
+35% +$2.92K ﹤0.01% 1787
2025
Q1
$7.04K Hold
4,000
– – ﹤0.01% 1767
2024
Q4
$10.6K Hold
4,000
– – ﹤0.01% 1460
2024
Q3
$9.16K Buy
+4,000
New +$12.2K ﹤0.01% 1507

Other funds holding NUVB

Larson Financial Group's NUVB Position: Q3 2026 in Review

Larson Financial Group increased its Nuvation Bio (NUVB) stake by 111% in Q3 2026, buying an estimated $194 and bringing the position to 59 shares worth $330. The position accounts for ﹤0.01% of the portfolio, ranked #3652.

Larson Financial Group first reported a position in NUVB in Q3 2024 and has held it in 7 quarters since. The position peaked at $20K in Q3 2025. 254 funds tracked by Wall St. Rank hold NUVB as of Q3 2026.

  • Larson Financial Group held 59 shares of Nuvation Bio worth $330 as of Q3 2026.
  • Larson Financial Group bought 31 Nuvation Bio shares in Q3 2026, an estimated $194.
  • Nuvation Bio made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #3652 holding.
  • Larson Financial Group first reported a position in Nuvation Bio in Q3 2024 and has held it in 7 quarters since.
  • Larson Financial Group's Nuvation Bio position peaked at $20K in Q3 2025.
  • 254 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.